Okay, right after lunch, and I know the food is making it your eyelid, but I promise to be to keep you awake. Answer to your first question, yes, it is possible. Answer to your second question, no, we haven't made it yet. Of course, we are still working on it. Otherwise, why would be here looking for investors. So early detection of cancer does indeed save lives, and I've had first hand experience with it, with my own sister, who's cancer, who's breast cancer, was detected early. She's been a long time survivor for many, many years. Late detection does result in loss of life, for sure, unfortunately, I have experienced that the first hand as well. My other sister, young and beautiful, she lost her battle and lost her life. That event, which was the most tragic event of my life, triggered something in me exactly 4am January 1, 2001 I remember the beginning of this journey where a passion was developed in me, intense passion to see what technology can do in the fight it to help the fight against cancer. As a hard core electrical engineer, I got interested in this subject, it was a long term passion. For a long time as an engineer, I tried to learn a tiny bit of biology, which was lucky that I didn't know a lot, because it teaches you to think differently when you have an engineering look. And finally, in 2016 I quit a dream job to start this biotech to develop the product that we are talking about in here, cancer, for all practical purposes, is, as far as we are concerned, a random event. One day you find that you have cancer and you have to do something about it. Now in order to catch a random event as early as possible. It's very obvious. You have to be able to sample it frequently, high sampling frequency to be able to catch this event. You don't know when it's going to happen. In order to do that, you need a test. You need a device that is low cost and affordable, of course, so you can do this regularly, in our case, every month that is reliable, that can work on majority of cancers, which our device is supposed to you can never claim all cancers, but majority, the first four we have focused on is lung, breast, prostate and colon, which constitutes 50% of all cancers in the World. So by itself, is very significant. And the device has to use a small amount of sample, and you have to be able to easily use that every month to be able to catch the onset of cancer. Not only that, if you're using this regularly, you're going to establish a trend line, which becomes extremely important to look at later. So, of course, a very tall order, extremely challenging, no doubt. And that is why we have been at this for eight years, developing all kinds of technologies and techniques and assays and everything else that need to come together to be able to produce such a device. Are we are not after a solving a corner of this problem. This is A to Z, from the very beginning to the end, also to the point of when the test is positive. Now, what do you do? You hold the patient's hand in what are all the next steps? This is a screening test. It doesn't identify the tissue of origin. At first, it first detects, it detects the presence of cancer, and once it is positive, then you go after identifying the tissue of origin. But the important point is that all of that has to take place at the cost of $50 per month, right at that that's a huge challenge, which, at the same time, makes it quite interesting and fun to work on this problem. So we've had to this is a totally multidisciplinary problem. You have to bring in all of these fields together, biology, biochemistry, electronics, sensing, mechanical design, micro fluidics. Regulatory concerns, all of these have to come together to be able to produce this final design as a product. Again, the engineering background in me has always emphasized on you need to keep your eye on the final product. You have to be able to produce this in volume, and that that is very crucial right from the beginning, when you think about what kind of solutions you're going to come up with in order to do this so, and that's why has been taken, has taken so long to put all of this together. We have a portfolio of IP portfolio of 58 patents that protects our i. Assays, technologies and everything else that we've done. And this one slide is the combination of 300 slides eight years of work, trying to all show it in one but it constitutes all of the elements of this work that makes it unique and possible, and we are getting closer and closer to accomplishing this. We have an exclusive, proprietary antibody that detects a target on exosomes that come from cancer cells. We have, we manufacture, produce and purify this antibody, we have the worldwide right to it in perpetuity. No one else has it. We have a patented exosome assay that works with this antibody, in order to do this cheaply and keep it at low cost and rapidly and make it a home test at the end, we have worked on two parallel tracks. One is the lateral flow assay technology that in new Lara flow assay digitally flow control, lateral flow assay technology that we have developed and patented and protected and and the other is based on a new micro fluidics technology that includes bio bio sensing and bio transistor sensing. We also, on top of this, have a distribution system that distributes test it's planned. Distribution system distributes, tracks results and then holds your hand in what you're going to do next once it is positive. The portal is called cancernot.com it's not active yet, but it will be. And as I mentioned, is a portfolio of FDA patents that protects our technologies. Look at the market, the general cancer screening market, cancer test and screening market in general, worldwide, is the relatively large market, but for this specific kind of, what we call affordable cancer screening for all that's our model. This is sort of a developing market. You can have many models and scenarios and whatnot. Unlike many startups, we do not do any revenue predictions and whatnot. I've been involved in the acquisition process of 63 startups as part of bigger companies. Not a single one of them actually sticks to what they predict so and we don't do that, all right? We ask our investors, you look at that, what we have, it's easy to model it. You decide whether we're going to capture point or 1% of it, or 10% of it, or whatever, and make your decision, we you're honest and say, We just can't do any predictions like that. But every which way you look at this, whether this is as a point of care, test as a home, test as a lab, test as a beginning. You use it every month. You use it every six months. You use it at first, on existing cancer patients for monitoring them. You use it on general population. There are many different scenarios, and every which way you look at it, it's significant snapshot of some early results on the performance of that antibody that captures the target on the X exosomes. And this is data from 837 human serum samples with 218 healthy subjects. 619 cancer patients, breast, lung, colon and prostate stages, one through four, that many subjects in each that's listed in that table, and this overall graph shows a sensitivity of 95.6% 4.4% false negative, and a specificity of 92.2% or 7.8% false positive. These numbers for those cancers are very significant for those of you who are familiar with with with the specific sensitivity of different cancers. It's not to claim that we are done. This is done inside the lab as a lab test with detailed protocols and procedures. We do not hype anything. We do not we don't even, we don't even have website. We don't first five years of this company, I support the company. We didn't even go to any investors whatsoever, because we wanted to get it to a point that is truly, truly presentable, and it's leading to a final product.
As far as, I don't call this competition, as far as the landscape, the two closest efforts to what we are trying to do as general cancer screening are Grail and thrive. Both were acquired, one for $7.1 billion one for $2.1 billion at the point that there was no revenue, no FDA approvals, nothing, and we don't call them competition. We love what they do. We want them extremely successful. We are totally complimentary to them. They are complementary to us. They're based on on DNA tests. We are based on a detection of this particular antigen on this. Difference of exosomes, two orthogonal routes that are going to reinforce each other in terms of results, there are ways of combining it, and this table lists the comparison of whether they are point of care. No, they are not. Price wise, about $1,000 or $950 for Gradle test, $50 for what we are trying to do, which is not out yet again, don't come asking me, Where is the cartridge and the specificity sensitivity comparison where, okay, there's a very good specificity on 99% 1% false positive, but average sensitivity of 50% so you miss 50% of their positive cases. Despite that, that has great value. And I would actually encourage everyone to go and take these tests, and the Crail is available to take. We are doing a Series A round for seven and a half million dollars. We have done $2 million of it. Five and a half is left at the $30 million pre money valuation. And this money, in 18 months to two years, is supposed to get us to a point where we are at the pre submission level, not FDA submission. We're not too naive to think, with that much money he can get get here to launch an FDA process, but that's in order to get it to that point and collect a lot of data, I'm running out of time. I wish I had another hour to enumerate all the accomplishments of this highly experienced team that I'm proud of, more than 450 years of collective experience, more than 1600 patents to their names in all of the related fields that we have to work on and collaborators. Brown University, DC and diagnostics, if you work in lateral flow, you know them, icon for regulatory strategy and antibody production company, Pacific Medical Laboratory, by IVT biotech. Those are all of collaborators. I think, I think I got it done on time because it says zero doesn't go negative. I.